EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted Alpha-Particle Therapy: A Review of Current Trials

Albert Jang iD, Ayse T Kendi iD, Geoffrey B Johnson, Thorvardur R Halfdanarson iD, Oliver Sartor

International Journal of Molecular Sciences · 19.07.2023 · 24 (14) · 11626

DOI: 10.3390/ijms241411626 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.07.2023. Verfasst von Albert Jang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiopharmaceuticals. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiopharmaceuticals are rapidly developing as a field, with the successful use of targeted beta emitters in neuroendocrine tumors and prostate cancer serving as catalysts. Targeted alpha emitters are in current development for several potential oncologic indications. Herein, we review the three most prevalently studied conjugated/chelated alpha emitters (225actinium, 212lead, and 211astatine) and focus on contemporary clinical trials in an effort to more fully appreciate the breadth of the current evaluation. Phase I trials targeting multiple diseases are now underway, and at least one phase III trial (in selected neuroendocrine cancers) is currently in the initial stages of recruitment. Combination trials are now also emerging as alpha emitters are integrated with other therapies in an effort to create solutions for those with advanced cancers. Despite the promise of targeted alpha therapies, many challenges remain. These challenges include the development of reliable supply chains, the need for a better understanding of the relationships between administered dose and absorbed dose in both tissue and tumor and how that predicts outcomes, and the incomplete understanding of potential long-term deleterious effects of the alpha emitters. Progress on multiple fronts is necessary to bring the potential of targeted alpha therapies into the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiopharmaceuticalsHumansMaleAlpha ParticlesClinical Trials as Topic

Stichwörter der Autor:innen

actinium-225astatine-211lead-212radiopharmaceuticalstargeted alpha therapy

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA.
  • Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Urology, Mayo Clinic, Rochester, MN 55905, USA.

ORCID-Profile: Albert Jang, Ayse T Kendi, Thorvardur R Halfdanarson

Zitieren

APA

Jang, A., Kendi, A. T., Johnson, G. B., Halfdanarson, T. R., & Sartor, O. (2023). Targeted Alpha-Particle Therapy: A Review of Current Trials. International Journal of Molecular Sciences, 24(14), 11626. https://doi.org/10.3390/ijms241411626

Vancouver

Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted Alpha-Particle Therapy: A Review of Current Trials. International Journal of Molecular Sciences. 2023;24(14):11626. doi:10.3390/ijms241411626

BibTeX
@article{Jang2023,
  author = {Jang, Albert and Kendi, Ayse T and Johnson, Geoffrey B and Halfdanarson, Thorvardur R and Sartor, Oliver},
  title = {Targeted Alpha-Particle Therapy: A Review of Current Trials},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {14},
  pages = {11626},
  doi = {10.3390/ijms241411626}
}
Kostenlos starten →